|

Sapanisertib Clinical Trials

3 actively recruiting trials across 3 locations

No change since May 2026

Also known as: FTH-003, INK-128, INK128, MLN-0128, MLN0128 +1 more

Pipeline

Phase 2: 1Phase 1/2: 2

Top Sponsors

  • Faeth Therapeutics2
  • National Cancer Institute (NCI)1

Indications

  • Cancer3
  • Liver Disease1
  • Stage IV Hepatocellular Carcinoma AJCC v81
  • Stage III Hepatocellular Carcinoma AJCC v81
  • HR+/HER2- Breast Cancer1

Irvine, California1 trial

Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

Phase 1/2

La Jolla, California1 trial

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

UC San Diego Moores Cancer Center

Phase 2

Los Angeles, California1 trial

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

START Los Angeles

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.